Mankind Pharma Ltd

Mon 24/08/2026,15:31:29 | NSE : MANKIND

₹2374.50-9.50 (-0.40%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2385.00

Previous Close

₹ 2384.00

Volume

130470

Mkt Cap ( ₹ Cr)

₹ 98065.89

High

₹ 2385.10

Low

₹ 2367.10

52 Week High

₹ 2674.00

52 Week Low

₹ 1909.70

Book Value Per Share

₹ 408.49

Dividend Yield

0.04

Face Value

₹ 1.00

What's Your Call?

Collective community sentiment on Mankind Pharma Ltd

Your Vote -

Buy

44.29%

Hold

24.29%

Sell

31.43%

44.29%

140 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

2374.50

14

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

14

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Mankind Pharma Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Mankind Pharma - General Updates

    22 Aug 2026, 2:01PM Mankind Pharma Limited has informed the Exchange about General Updates
  • Mankind Pharma - Intimation Regarding ESG Rating

    22 Aug 2026, 1:59PM Please find attached intimation regarding ESG Rating
  • Mankind Pharma - Press Release

    20 Aug 2026, 1:38PM Mankind Pharma Limited has informed the Exchange regarding a press release dated August 20, 2026, titled ""Mankind Pharma Enters into Exclusive In-Lic
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    20 Aug 2026, 1:35PM Please find attached press release dated August 20, 2026.
  • Mankind Pharma signs exclusive in-licensing deal for Insulin Products in India

    20 Aug 2026, 1:30PM Mankind Pharma Ltd has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical Co Ltd for t
  • Mankind Pharma - Copy of Newspaper Publication

    19 Aug 2026, 10:26AM Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Mankind Pharma - Shareholders meeting

    18 Aug 2026, 3:52PM Mankind Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    18 Aug 2026, 3:48PM Please find attched postal ballot notice
  • Mankind Pharma - General Updates

    17 Aug 2026, 11:10PM Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVacci
  • Mankind Pharma - Completion Of Realignment Of Security Cover In Respect Of Non-Convertible Debentures And Consequent Release

    17 Aug 2026, 11:04PM Completion of realignment of Security Cover in respect of Non-Convertible Debentures.
  • Mankind Pharma - Acquisition

    13 Aug 2026, 9:31PM Mankind Pharma Limited has informed the Exchange about Acquisition
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    13 Aug 2026, 9:29PM Please find attached intimation regarding incorporation of a wholly owned subsidiary company in Netherlands
  • Mankind Pharma - Appointment

    10 Aug 2026, 4:17PM Mankind Pharma Limited has informed the Exchange regarding Appointment of Mr Anish Vanraj Bafna as Non- Executive Independent Director of the company
  • Mankind Pharma - Outcome of Board Meeting

    10 Aug 2026, 4:13PM Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026.
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 12:43PM Mankind Pharma Limited has informed the Exchange about Schedule of meet
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Change in Management

    10 Aug 2026, 4:23PM Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Directo
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Change in Management

    10 Aug 2026, 4:22PM Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Directo
  • Mankind Pharma - Board Meeting Outcome for For Appointment Of An Additional Director Designated As Non-Executive Independent

    10 Aug 2026, 4:10PM Please find attached outcome of board meeting
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Aug 2026, 12:38PM Please find attached intimation regarding participation in Investor Conferences
  • Mankind Pharma - Shareholders meeting

    6 Aug 2026, 4:01PM Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 04, 2026. Further, the company h
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholders meeting

    4 Aug 2026, 5:32PM Mankind Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 04, 2026
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Aug 2026, 1:14PM Mankind Pharma Limited has informed the Exchange about Transcript
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    6 Aug 2026, 3:59PM Please find attached Voting Results and Scrutinizer's Report of 35th AGM
  • Mankind Pharma - Shareholder Meeting / Postal Ballot-Outcome of AGM

    4 Aug 2026, 5:36PM Please find attached proceedings of the 35th AGM of the Company
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    4 Aug 2026, 1:25PM Please find attached transcript of the Investor Conference call for Q1FY27 held on July 30, 2026
  • Mankind Pharma - Copy of Newspaper Publication

    31 Jul 2026, 3:02PM Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Jul 2026, 8:31PM Investor Conference call for Q1FY27 - Audio Recording
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jul 2026, 8:28PM Mankind Pharma Limited has informed the Exchange about Link of Recording
  • Mankind Pharma - General Updates

    30 Jul 2026, 4:01PM Please find attached certificate under Regulation 54 of the SEBI (LODR) Regulations, 2015
  • Mankind Pharma - Compliances-Reg. 54 - Asset Cover details

    30 Jul 2026, 3:59PM Please find attached certificate under Regulation 54 of the SEBI (LODR) Regulations, 2015
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jul 2026, 3:55PM Please find attached press release on financial results of the Company for Q1FY27
  • Mankind Pharma - Press Release

    30 Jul 2026, 3:53PM Mankind Pharma Limited has informed the Exchange regarding a press release dated July 30, 2026, titled ""Press Release on Financial Results for Q1FY27
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    30 Jul 2026, 3:48PM Please find attached investor presentation for Q1FY27
  • Mankind Pharma - Investor Presentation

    30 Jul 2026, 3:46PM Mankind Pharma Limited has informed the Exchange about Investor Presentation
  • Mankind Pharma - Approval For Issuance Of Corporate Guarantee

    30 Jul 2026, 3:41PM Board of Directors of the Company in its meeting held today has inter-alia considered and approved the issuance of corproate guarantee in favour of Bh
  • Mankind Pharma - Giving guarantees/indemnity/ becoming a surety for third party

    30 Jul 2026, 3:31PM Mankind Pharma Limited has informed the Exchange about Giving guarantees/indemnity/ becoming a surety for third party
  • Mankind Pharma - Un-Audited Financial Results Of The Company For The Quarter Ended On June 30, 2026

    30 Jul 2026, 3:29PM Please find attached un-audited financial results of the Company for the quarter ended on June 30, 2026
  • Mankind Pharma - Board Meeting Outcome for Outcome Of Board Meeting

    30 Jul 2026, 3:23PM Outcome of Board Meeting
  • Mankind Pharma - Outcome of Board Meeting

    30 Jul 2026, 3:22PM Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Mankind Pharma - General Updates

    27 Jul 2026, 6:30PM Final update on Stake Sale of Broadway Hospitality Services Private Limited
  • Mankind Pharma - Final Update On Stake Sale Of Broadway Hospitality Services Private Limited

    27 Jul 2026, 6:14PM Intimation under Regulation 30 of the SEBI LODR
  • Mankind Pharma has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    20 Jul 2026, 8:20PM As of June 2026, 72.63% is owned by Indian Promoters and 27.37% by Public. <p align=justify> Institutional holds 24.84% (Insurance Companies 1.54%) an
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Jul 2026, 3:40PM Please find attached intimation regarding investor conference call for Q1FY27.
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Jul 2026, 3:36PM Mankind Pharma Limited has informed the Exchange about Schedule of meet
  • Mankind Pharma - Board Meeting Intimation for Approval Of Financial Results

    16 Jul 2026, 4:32PM Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and a
  • Mankind Pharma - Acquisition

    11 Jul 2026, 1:29PM Mankind Pharma Limited has informed the Exchange about Acquisition
  • Mankind Pharma - Diversification/Disinvestment

    11 Jul 2026, 1:27PM Mankind Pharma Limited has informed the Exchange about Diversification/Disinvestment
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    11 Jul 2026, 1:27PM Board of Directors of the Company in its meeting held today i.e., July 11, 2026 has approved the incorporation of a wholly owned subsidiary in Netherl
  • Mankind Pharma - Outcome of Board Meeting

    11 Jul 2026, 1:24PM Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 11, 2026.
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment

    11 Jul 2026, 1:31PM Board of Directors of the Company has approved the divestment of 100 % stake held in Broadway Hospitality Services Private Limited, a wholly owned sub
  • Mankind Pharma - Board Meeting Outcome for Outcome Of Board Meeting

    11 Jul 2026, 1:23PM Please find attached Outcome of Board Meeting held on July 11, 2026
  • Mankind Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Jul 2026, 11:12AM Please find attached certificate under Regulation 74(5) of the SEBI DP Regulations, 2018 for the quarted ended on June 30, 2026
  • Mankind Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Jul 2026, 11:09AM Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Mankind Pharma - Copy of Newspaper Publication

    10 Jul 2026, 9:41AM Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Mankind Pharma - Shareholders meeting

    9 Jul 2026, 4:37PM Mankind Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 04, 2026
  • Mankind Pharma - Business Responsibility and Sustainability Reporting (BRSR)

    9 Jul 2026, 5:04PM Please find attached BRSR Report for the financial year 2025-26
  • Mankind Pharma - Regulation 53 (1) Annual Report.

    9 Jul 2026, 4:56PM Please find attached Annual Report of the Company for financial year 2025-26
  • Mankind Pharma - Reg. 34 (1) Annual Report.

    9 Jul 2026, 4:47PM Please find attached Annual Report of the Company for the financial year 2025-26
  • Mankind Pharma - Notice Of 35Th AGM

    9 Jul 2026, 4:35PM Please find attached notice of 35th Annual General Meeting of the Company
  • Mankind Pharma - Copy of Newspaper Publication

    1 Jul 2026, 11:20AM Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Mankind Pharma - General Updates

    30 Jun 2026, 11:55AM Mankind Pharma Limited has informed the Exchange about General Updates
  • Mankind Pharma - Intimation Of Date Of AGM

    30 Jun 2026, 11:59AM Please find attached Intimation of the date of Thirty Fifth (35th) Annual General Meeting of the Company.
  • Mankind Pharma - Trading Window

    25 Jun 2026, 12:29PM Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2
  • Mankind Pharma - Disclosure under SEBI Takeover Regulations

    10 Jun 2026, 3:57PM ÿRamesh Junejaÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac
  • Mankind Pharma - Cessation

    8 Jun 2026, 10:34PM Mankind Pharma Limited has informed the Exchange regarding Cessation of Mr Prateek Dubey as SMP of the company w.e.f. Jun 08, 2026.
  • Mankind Pharma - Appointment

    8 Jun 2026, 10:32PM Mankind Pharma Limited has informed the Exchange regarding Appointment of Mr Nilesh Kulkarni as SMP of the company w.e.f. Jun 08, 2026.
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Change in Management

    8 Jun 2026, 10:22PM Please find attached Intimation regarding Change in Management.
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    8 Jun 2026, 6:16PM Allotment of 86,778 Equity Shares under Mankind Employee Stock Option Plan 2022 (\ESOP PLAN\)
  • Mankind Pharma - Allotment of Securities

    8 Jun 2026, 6:14PM Mankind Pharma Limited has informed the Exchange regarding allotment of 86778 securities pursuant to ESOP/ESPS at its meeting held on Jun 08, 2026
  • Mankind Pharma - Acquisition

    2 Jun 2026, 5:45PM Mankind Pharma Limited has informed the Exchange about Acquisition
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    2 Jun 2026, 5:38PM Please find attached Intimation regarding acquisition of stake by a wholly owned subsidiary company.
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    27 May 2026, 4:11PM Mankind Pharma Limited has informed the Exchange about Schedule of meet
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    27 May 2026, 4:15PM Please find attached intimation regarding participation in investor conference
  • Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    26 May 2026, 5:02PM Mankind Pharma Limited has informed the Exchange about Transcript
  • Mankind Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    26 May 2026, 5:01PM Please find attached transcript of the Investor Conference Call held on May 20, 2026
  • Mankind Pharma acquires Rivotril brand for India

    18 Mar 2026 , 10:35AM Rivotril widely prescribed for mgmt of neurological & psychiatric conditions
  • Mankind Pharma

    18 Sep 2024 , 10:52AM Mankind Pharma : Company's board to consider raising funds via NCDs, commercial papers, other debt securities among others on September 20. (Stock not under coverage)
  • Mankind Pharma

    10 Jul 2024 , 10:34AM Hema CIPEF to sell 0.9% stake worth Rs 763crore. Deal is expected at Rs 2061/share which is at 2% discount to previous closing price. Hema CIPEF currently owns 2.22% stake.
  • Mankind Pharma

    14 May 2024 , 12:15PM The Company is looking to acquire Bharat Serum and vaccines from PE Company Advent which has 100% ownership of Bharat Serum & vaccines & now is looking to exit. Positive read through.

Key fundamentals

Evaluate the intrinsic value of Mankind Pharma Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 21885.2 21888.52 9623.8091 7783.911 6756.6684
Liabilities 21885.2 21888.52 9623.8091 7783.911 6756.6684
Equity 41.28 41.26 40.0588 40.0588 40.0588
Gross Profit 3085.92 2562.55 2325.1047 1697.3814 1799.6143
Net Profit 2037.56 1945.48 1823.4096 1248.258 1335.1306
Cash From Operating Activities 2751.99 2322.16 1982.9732 1798.9871 812.2873
NPM(%) 19.55 20.48 19.68 15.35 18.39
Revenue 10421.18 9497.8 9264.8093 8127.1532 7257.0359
Expenses 7335.26 6935.25 6939.7046 6429.7718 5457.4216
ROE(%) 12.07 11.53 10.8 7.39 7.91

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
08 Aug 2025 1 100 0.04 2567.2

Peers

Other companies within the same industry or sector that are comparable to Mankind Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 888.70 2.84 22.48 1353.75 -26.19 0.56
Lotus Eye Hospital and Institute Ltd 115.50 -0.09 1650.00 4932.88 0.39 0.00
Vaishali Pharma Ltd 8.12 1.63 25.37 30945.61 15.42 0.00
Astec Lifesciences Ltd 592.70 -1.52 0.00 5285.31 -363.14 0.00

Company Info

The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 -Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others2005 -Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited2009 -Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 -Launched `Preganews' brand in the consumer healthcare segment2012 -Setup the first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated the Subsidiary, Lifestar Pharma LLC in the US-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 -Set up the manufacturing facility in Sikkim2018 -The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 -Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.2024-Mankind Pharma Completes Landmark Acquisition of BSV.-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain). 2025-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited  and Jaspack Industries Private Limited  with Mankind Pharma Limited

The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 -Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others2005 -Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited2009 -Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 -Launched `Preganews' brand in the consumer healthcare segment2012 -Setup the first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated the Subsidiary, Lifestar Pharma LLC in the US-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 -Set up the manufacturing facility in Sikkim2018 -The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 -Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.2024-Mankind Pharma Completes Landmark Acquisition of BSV.-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain). 2025-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited  and Jaspack Industries Private Limited  with Mankind Pharma Limited

Parent Organisation

Mankind Pharma Ltd.

Founded

03/07/1991

Managing Director

Mr.Rajeev Juneja

NSE Symbol

MANKINDEQ

FAQ